Exact Sciences (NASDAQ: EXAS) and Roka Bioscience (NASDAQ:ROKA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares Exact Sciences and Roka Bioscience’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Exact Sciences $99.38 million 71.41 -$167.21 million ($1.16) -51.09
Roka Bioscience $7.24 million 0.78 -$30.78 million ($14.20) -0.08

Roka Bioscience has higher revenue, but lower earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Roka Bioscience, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Exact Sciences and Roka Bioscience, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exact Sciences 0 5 8 0 2.62
Roka Bioscience 0 0 1 0 3.00

Exact Sciences currently has a consensus price target of $50.77, indicating a potential downside of 14.34%. Roka Bioscience has a consensus price target of $10.00, indicating a potential upside of 792.86%. Given Roka Bioscience’s stronger consensus rating and higher probable upside, analysts plainly believe Roka Bioscience is more favorable than Exact Sciences.


This table compares Exact Sciences and Roka Bioscience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Exact Sciences -60.71% -30.32% -27.37%
Roka Bioscience -409.83% -121.16% -68.51%

Institutional and Insider Ownership

86.0% of Exact Sciences shares are held by institutional investors. Comparatively, 66.9% of Roka Bioscience shares are held by institutional investors. 4.0% of Exact Sciences shares are held by insiders. Comparatively, 29.2% of Roka Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Exact Sciences has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Roka Bioscience has a beta of 2.29, suggesting that its share price is 129% more volatile than the S&P 500.


Exact Sciences beats Roka Bioscience on 8 of the 13 factors compared between the two stocks.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.

About Roka Bioscience

Roka Bioscience, Inc. is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company’s Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.